Evidence map›Paper›PMID 36580014›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2022

Awareness about Human Papillomavirus Vaccine and Its Uptake among Women from North India: Evidence from a Cross-Sectional Study.

Ataur Rehman, Shobhit Srivastava, Priyanka Rani Garg, Rishi Garg, Kauma Kurian, Shumayla Shumayla, Suresh Kumar Rathi, Sunil Mehra

Open access · goldAbstract read
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Ataur RehmanMAMTA Health Institute for Mother and Child, B-5, Greater Kailash Enclave-II, New Delhi, India.
Shobhit SrivastavaMAMTA Health Institute for Mother and Child, B-5, Greater Kailash Enclave-II, New Delhi, India.ORCID 0000-0002-7138-4916
Priyanka Rani GargMAMTA Health Institute for Mother and Child, B-5, Greater Kailash Enclave-II, New Delhi, India.ORCID 0000-0002-9752-8762
Rishi GargMAMTA Health Institute for Mother and Child, B-5, Greater Kailash Enclave-II, New Delhi, India.
Kauma KurianMAMTA Health Institute for Mother and Child, B-5, Greater Kailash Enclave-II, New Delhi, India.ORCID 0000-0003-1287-1404
Shumayla ShumaylaMAMTA Health Institute for Mother and Child, B-5, Greater Kailash Enclave-II, New Delhi, India.ORCID 0000-0002-9217-6550
Suresh Kumar RathiDepartment of Central Research and Innovation, Sumandeep Vidyapeeth Deemed to be University, Vadodara, India.ORCID 0000-0002-8480-1627
Sunil MehraMAMTA Health Institute for Mother and Child, B-5, Greater Kailash Enclave-II, New Delhi, India.ORCID 0000-0001-7414-7054
Mamta Health Institute for Mother and Child · INSuamandeep Vidyapeeth University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study aims to estimate the prevalence of human papillomavirus (HPV) vaccine usage and determine the factors for awareness about HPV vaccine among women in reproductive age group.

methodsThis is a cross-sectional survey under a cervical cancer prevention study. The sample size was 1020 women, aged 15-49 years [550 in Delhi and 470 in Rohtak]. Bivariate analysis and Fisher exact test along with binary logistic regression analysis were used to determine the factors for awareness.

resultAbout 18.0 % [Delhi: 24.2 % and Rohtak: 10.9 %] of the respondents had heard about the vaccine against cervical cancer. The women aged more than 30 years [AOR: 1.35; CI: 0.94, 1.94] were more likely to be aware of cervical cancer vaccine as compare to women of 30 years and less. However, the women from Rohtak [AOR: 0.90; CI: 0.48, 1.66] were less likely to be aware of vaccine against cervical cancer in reference to women aged 30 years and more [AOR: 1.61; CI: 1.01, 2.56] from Delhi. About 0.6 % [Delhi: 1.1 % and Rohtak: 0.0 %] of the respondents had received HPV vaccine.

conclusionWomen tend to have limited knowledge about cervical cancer vaccine and immunisation practices. The women's demographic makeup varied significantly between the two sites, i.e , Rohtak and Delhi, which had an impact on how well they understood and utilised the cervical cancer vaccination. It is worth mentioning that none of the women from Rohtak had received the immunisation. The awareness of the cervical cancer vaccine among women from the Rohtak was lower than the Delhi women.

Indexed as

Cancer VaccinesPapillomavirus InfectionsPapillomavirus VaccinesUterine Cervical NeoplasmsCross-Sectional StudiesFemaleHealth Knowledge, Attitudes, PracticeHuman Papillomavirus VirusesHumansIndiaSurveys and QuestionnairesVaccinationCancer VaccinesPapillomavirus VaccinesCervical cancerHuman Papillomavirus VaccinesVaccinationVaccine Awareness, India

Identifiers

PMID36580014
PMCPMC9971470
OpenAlexW4313328657

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.